Novartis AG (NVS)
Automate Your Wheel Strategy on NVS
With Tiblio's Option Bot, you can configure your own wheel strategy including NVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVS
- Rev/Share 28.044
- Book/Share 21.5883
- PB 5.7735
- Debt/Equity 0.7773
- CurrentRatio 0.8179
- ROIC 0.1849
- MktCap 240887492759.0
- FreeCF/Share 8.6273
- PFCF 14.3334
- PE 25.2052
- Debt/Assets 0.3126
- DivYield 0.0321
- ROE 0.2294
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVS | Goldman | Neutral | Sell | -- | $118 | Sept. 12, 2025 |
| Upgrade | NVS | Morgan Stanley | Underweight | Equal Weight | -- | $123 | Aug. 8, 2025 |
| Downgrade | NVS | UBS | Buy | Neutral | -- | -- | Feb. 13, 2025 |
| Initiation | NVS | Morgan Stanley | -- | Underweight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVS | Deutsche Bank | Hold | Buy | -- | -- | Feb. 4, 2025 |
| Downgrade | NVS | HSBC Securities | Hold | Reduce | -- | -- | Dec. 4, 2024 |
| Downgrade | NVS | BofA Securities | Buy | Neutral | $135 | $130 | Sept. 11, 2024 |
| Downgrade | NVS | Goldman | Buy | Neutral | -- | -- | Sept. 5, 2024 |
| Downgrade | NVS | Jefferies | Buy | Hold | -- | -- | Sept. 3, 2024 |
News
Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Final Trades: Novartis, Sixth Street, Amazon and the IYF
Published: June 26, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Novartis completes acquisition of Regulus Therapeutics
Published: June 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.
Read More
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
Buy These 5 Low-Leverage Stocks Amid Fresh Iran-Israel War
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
As markets reel under the Israel-Iran conflict, NVS, ENSG, MTZ, BILI and STRL stocks offer a safer path through volatility.
Read More
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Top Cancer Stocks to Supercharge Your 2025 Portfolio
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Read More
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Novartis (NVS) Could Be a Great Choice
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Read More
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Published: June 02, 2025 by: Reuters
Sentiment: Positive
Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a drug technology that the drugmaker has pioneered.
Read More
Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial
Published: June 02, 2025 by: WSJ
Sentiment: Positive
Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.
Read More
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, …
Read More
Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
NVS, ENGIY, MTZ, DORM and STRL offer low leverage and earnings growth, making them safer picks during periods of volatile market sentiment.
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Read More
Here's Why Novartis (NVS) is a Strong Value Stock
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Novartis (NVS) Upgraded to Buy: What Does It Mean for the Stock?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Should Value Investors Buy Novartis (NVS) Stock?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Novartis to keep making malaria drugs if orders dry up amid aid cuts
Published: May 12, 2025 by: Reuters
Sentiment: Positive
Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told Reuters in an interview.
Read More
Here's Why Novartis (NVS) is a Strong Momentum Stock
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Novartis (NVS) is a Great Momentum Stock: Should You Buy?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Why Novartis (NVS) is a Great Dividend Stock Right Now
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Read More
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Published: April 30, 2025 by: Benzinga
Sentiment: Positive
Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.
Read More
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Positive
Novartis' Q1 2025 results validate our investment thesis. They showcase double-digit sales growth and robust margins, reinforcing our overweight position. Novartis announced a $23 billion US investment, bolstering our positive outlook amid pharma tariff uncertainties. It also raised its FY 2025 outlook. Despite patent expirations, Novartis' strong cash flow, ongoing buyback, and low-risk profile support our continued buy rating.
Read More
Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, with Focus on Novartis
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure, and innovative treatments are driving growth. Novartis AG leads, with North America as the largest market and Asia-Pacific fastest-growing. In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure, and innovative treatments are driving growth. Novartis AG leads, with North America as the largest market and Asia-Pacific fastest-growing.
Read More
Novartis to Acquire Regulus in $1.7 Billion Deal
Published: April 30, 2025 by: WSJ
Sentiment: Positive
With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.
Read More
Novartis to buy Regulus Therapeutics for up to $1.7 billion
Published: April 30, 2025 by: Reuters
Sentiment: Positive
Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.
Read More
Novartis CEO on minimizing the impact of potential tariffs on the pharmaceutical industry
Published: April 29, 2025 by: CNBC Television
Sentiment: Neutral
Vasant Narasimhan, Novartis CEO, discusses the impact of potential tariffs.
Read More
About Novartis AG (NVS)
- IPO Date 1996-11-07
- Website https://www.novartis.com
- Industry Drug Manufacturers - General
- CEO Vasant Narasimhan
- Employees 75883